Source link : https://www.newshealth.biz/health-news/fda-staff-questions-safety-of-mdma-treatment-for-ptsd/
FDA staff raised concerns about the available safety data and limitations in the study design for midomafetamine (MDMA) to treat post-traumatic stress disorder (PTSD) in briefing documents released ahead of an FDA Psychopharmacologic Drugs Advisory Committee (PDAC) meeting. If eventually approved by the agency, Lykos Therapeutics’ MDMA could become a first-in-class treatment for PTSD, which […]
Author : News Health
Publish date : 2024-05-31 21:29:51
Copyright for syndicated content belongs to the linked Source.
Categories